JENNIFER CHOW: Open Payments
NPI 1730178104 · APO, AE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,567 in 74 payments from 13 companies in 2025. Trend: 2023 $1,031 · 2024 $1,457 · 2025 $1,567
Food & beverage: $1,567
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $290 |
| Otsuka America Pharmaceutical, Inc. | 12 | $256 |
| Janssen Pharmaceuticals, Inc | 5 | $225 |
| Axsome Therapeutics, Inc. | 14 | $193 |
| Corium, LLC | 9 | $180 |
| ABBVIE INC. | 6 | $114 |
| Tris Pharma Inc | 3 | $59 |
| Bausch Health US, LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Collegium Pharmaceutical, Inc. | 2 | $44 |
Products named: CAPLYTA, SPRAVATO, Auvelity, Azstarys, REXULTI, VRAYLAR, Dyanavel XR, APLENZIN.
Industry payments across AE — which companies pay providers there.
